At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 490 enrolled
Drug / intervention
TAU-284 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)
In Brief
A Phase 3 clinical trial evaluating TAU-284 and Placebo for Perennial Allergic Rhinitis. Completed, enrolled 490 participants across 5 sites.
Detailed Summary
The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and plasma concentrations of TAU-284.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerennial Allergic Rhinitis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionDec 2011
TodayJul 2026
First PostedAug 30, 2011
Enrollment StartAug 1, 2011
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.8 years ago
Interventions
TAU-284drug
TAU-284 Low
TAU-284drug
TAU-284 High
Placebodrug
Placebo